Colorectal cancer (CRC) is one of the most common forms of cancer, with an estimated 1.36
million new cases and almost 700,000 deaths annually. Approximately 21% of patients with …

Abstract Background Trifluridine/tipiracil (FTD/TPI) and regorafenib prolong survival for
patients with refractory metastatic colorectal cancer (mCRC); limited comparative …

Introduction: Intravenous administration of fluoropyrimidine-based chemotherapy has been
the cornerstone of treatment in metastatic colorectal cancer (mCRC) for decades. The …

Abstract Learning Objectives After completing this course, the reader will be able to: Identify
the advantages and disadvantages of the various chemotherapeutic regimens used to treat …

Background The optimal chemotherapeutic regimen for use beyond the second line for
patients with metastatic colorectal cancer (mCRC) remains unclear. Materials and methods …

The treatment of metastatic colorectal cancer (mCRC) has evolved significantly over the past
10 years. For nearly 40 years, the fluoropyrimidine 5-fluorouracil (5-FU) was the only agent …

Background Colorectal cancer (CRC) is common in North America. Metastatic disease is
present at diagnosis in 30% of the patients, and approximately half of early-stage patients …

Combinations of fluoropyrimidines with oxaliplatin or irinotecan plus a biologic agent are
standard treatments for metastatic colorectal cancer (mCRC). Recent approvals of first-line …

Regorafenib and trifluridine/tipiracil (TAS-102) are novel antitumor agents for patients with
refractory metastatic colorectal cancer. However, it is unclear which patients may derive a …

Opinion statement Despite advances in screening procedures and the use of adjuvant
therapy, approximately 50% of patients with colorectal cancer eventually will develop …